Activating a B cell immune response regresses immunologically cold tumours

Area of Science:

• Immunology
• Oncology
• Nanomedicine

Background:

• Immuno-oncology faces challenges with poorly immunogenic tumors and over-reliance on T cells.
• Other immune cells, like B cells, are underutilized in cancer therapy.

Purpose of the Study:

• To investigate the efficacy of AT-1965, a novel small molecule delivered via lipid nanoparticles, against cold tumors.
• To elucidate the mechanism of action of AT-1965, focusing on its interaction with CMTR2 and its impact on immune cell infiltration.

Main Methods:

• Administration of AT-1965 in lipid nanoparticles to tumor models.
• Analysis of tumor immune cell infiltration, particularly B cells.
• Genetic knockout of B cells to assess their role in AT-1965 efficacy.
• Correlation of CMTR2 expression with clinical outcomes.

Main Results:

• AT-1965 induced rapid regression of poorly immunogenic tumors.
• Treatment triggered an innate inflammatory viral defense response via CMTR2 interaction.
• AT-1965-treated tumors showed significant B cell infiltration.
• B cell depletion abrogated the anti-tumor efficacy of AT-1965.

Conclusions:

• AT-1965 demonstrates potent anti-tumor activity by targeting CMTR2 and recruiting B cells.
• B cells are critical mediators of AT-1965's anti-tumor effects.
• CMTR2 and B cell infiltration represent promising targets for novel immuno-oncology strategies.